DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Grows Stake in Bristol-Myers Squibb (NYSE:BMY)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 701.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,470,106 shares of the biopharmaceutical company's stock after buying an additional 10,913,708 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned about 0.61% of Bristol-Myers Squibb worth $705,309,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BMY. Vanguard Group Inc. boosted its stake in Bristol-Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after purchasing an additional 1,373,209 shares during the last quarter. Capital International Investors raised its holdings in Bristol-Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after acquiring an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock worth $2,505,967,000 after purchasing an additional 1,187,231 shares during the last quarter. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $1,989,525,000. Finally, Ameriprise Financial Inc. lifted its position in Bristol-Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after buying an additional 12,011,983 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BMY shares. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Citigroup raised their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Truist Financial increased their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $47.63 on Thursday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company has a market cap of $96.94 billion, a price-to-earnings ratio of -10.78, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The stock's 50-day moving average is $55.06 and its two-hundred day moving average is $56.27. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the firm earned ($4.40) earnings per share. The business's quarterly revenue was down 5.6% compared to the same quarter last year. Analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.21%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.